Login to Your Account



Versicor, Biosearch Merging In Stock Swap Valued At $261M

By Randall Osborne


Thursday, August 1, 2002
With the antibiotic dalbavancin in Phase II trials, Versicor Inc. said it has agreed to buy collaborator Biosearch Italia SpA - from which it gained the rights to the drug - for $260.7 million in a stock swap expected to close early next year. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription